Table 3.

The network meta-analysis of PFS in the overall population.

Olaparib	1.11(0.83, 1.50)	1.12(0.82, 1.52)	3.10(2.47, 3.90)
0.90(0.67, 1.21)	Niraparib	1.00(0.76, 1.33)	2.78(2.30, 3.38)
0.89(0.66, 1.21)	1.00(0.75, 1.32)	Rucaparib	2.78(2.27, 3.40)
0.32(0.26, 0.40)	0.36(0.30, 0.44)	0.36(0.29, 0.44)	Placebo

The data in bold are statistically significant.